Surgical treatment improves overall survival of hepatocellular carcinoma with extrahepatic metastases after conversion therapy: a multicenter retrospective study

作者：Xiaoshi Zhang, Xiaodong Zhu, Jian‐Hong Zhong, Yang Zhao, Xiaoyun Zhang, Wenwen Zhang, Feng Ye, Chaoxu Yang, Jun Xue, Rui Xiong, Jiabei Wang, Shunli Shen, Yangxun Pan, Dongxiao Li, Tianqiang Song, Xinyu Bi, Hui‐Chuan Sun, Bang‐De Xiang, Shanzhi Gu, Tianfu Wen, Shichun Lu, Yongjun Chen, Tao Yin, Lianxin Liu, Ming Kuang, Li Xu, Deyu Li, Jianqiang Cai · 发表于：Scientific Reports · 年份：2024 · DOI：10.1038/s41598-024-60379-x · 被引用次数：8 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Cholangiocarcinoma and Gallbladder Cancer Studies、Cancer, Lipids, and Metabolism

Systemic therapy is typically the primary treatment choice for hepatocellular carcinoma (HCC) patients with extrahepatic metastases. Some patients may achieve partial response (PR) or complete response (CR) with systemic treatment, leading to the possibility of their primary tumor becoming resectable. This study aimed to investigate whether these patients could achieve longer survival through surgical resection of their primary tumor. We retrospectively collected data from 150 HCC patients with extrahepatic metastases treated at 15 different centers from January 1st, 2015, to November 30th, 2022. We evaluated their overall survival (OS) and progress-free survival (PFS) and analyzed risk factors impacting both OS and PFS were analyzed. Patients who received surgical treatment had longer OS compared to those who did not (median OS 16.5 months vs. 11.3 months). However, there was no significant difference in progression-free survival between the two groups. Portal vein invasion (P = 0.025) was identified as a risk factor for poor prognosis in patients, while effective first-line treatment (P = 0.039) and surgical treatment (P = 0.005) were protective factors. No factors showed statistical significance in the analysis of PFS. Effective first-line treatment (P = 0.027) and surgical treatment (P = 0.006) were both independent protective factors for prolonging patient prognosis, while portal vein invasion was an independent risk factor (P = 0.044). HCC patients with extrahepatic met...